First Hemophilia B Patient Enrolled in Potential Breakthrough Phase III Trial

According to BioPortfolio, the company UniQure has recently announced that the first hemophilia B patient has been enrolled in their Phase III study of the treatment AMT-061, which is an…

Continue Reading First Hemophilia B Patient Enrolled in Potential Breakthrough Phase III Trial
UniQure Publishes Phase I/II Trial Results of AMT-060 Gene Therapy in Treating Hemophilia B
geralt / Pixabay

UniQure Publishes Phase I/II Trial Results of AMT-060 Gene Therapy in Treating Hemophilia B

Pharmaceutical company and gene therapy leader, uniQure, published promising data from their current phase I/II trial testing out a gene therapy called AMT-060 in patients with serious cases of hemophilia B.…

Continue Reading UniQure Publishes Phase I/II Trial Results of AMT-060 Gene Therapy in Treating Hemophilia B